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In 2002, we investigated a cluster of patients with Al-
caligenes xylosoxidans bloodstream infections by conduct-
ing a matched case–control study and a prospective study. 
Pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed on 
blood culture isolates, and 1 explanted central venous cath-
eter (CVC) was tested for bioﬁ  lm. We identiﬁ  ed 12 cases of 
A. xylosoxidans bloodstream infection. Case-patients were 
more likely than controls to have had a CVC (7/7 [100%] 
vs 4/47 [8.7%], respectively; p<0.0001). Ten case isolates 
were indistinguishable by PFGE analysis, and A. xylosoxi-
dans bioﬁ  lm from the CVC matched the outbreak strain. We 
observed multiple breaches in infection control, which may 
have caused contamination of multidose vials used to ﬂ  ush 
the CVCs. Our study links A. xylosoxidans with CVC bioﬁ  lm 
and highlights areas for regulation and oversight in outpa-
tient settings.
A
lcaligenes xylosoxidans, also known as Achromobacter 
xylosoxidans, is a gram-negative, water-borne organ-
ism that causes healthcare-associated infections (1–7) 
and bacteremia in immunocompromised patients with in-
dwelling catheters (6–11); it can also contaminate liquids 
(2,5,12–14). A. xylosoxidans is found in soil and water and 
grows in saline (15,16). On January 16, 2002, the Acute 
Communicable Disease Control (ACDC) program of the 
Los Angeles County Department of Public Health was no-
tiﬁ  ed by a local hospital epidemiologist about a cluster of 
patients with A. xylosoxidans bloodstream infections (17). 
The patients had been admitted to Hospital A over a period 
of 2 months.
To conﬁ  rm the presence of an outbreak, ACDC con-
ducted a telephone survey, which asked the microbiology 
laboratories of Hospital A and 4 surrounding hospitals for 
a list of all patients who had had positive blood cultures 
for A. xylosoxidans in the past 3 months. One laboratory 
identiﬁ  ed 3 such patients, and Hospital A laboratory iden-
tiﬁ  ed 7; all 9 patients (1 case-patient had positive blood 
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cultures reported from both laboratories) were associated 
with a single outpatient oncology ofﬁ  ce, Ofﬁ  ce B. The oth-
er 3 hospitals reported that they had not identiﬁ  ed any A. 
xylosoxidans bloodstream infections in the past 3 months. 
To identify the source of the outbreak and risk factors for 
infection and to implement control measures, ACDC then 
initiated an outbreak investigation.
Methods
The outbreak investigation focused on Ofﬁ  ce B. To 
identify all patients associated with Ofﬁ  ce B who had had a 
positive A. xylosoxidans culture, we requested a review of 
medical records and laboratory reports.
Matched Case–Control Study
A matched case–control study was performed to deter-
mine risk factors for infection. A case-patient was deﬁ  ned 
as a patient of Ofﬁ  ce B who had a positive A. xylosoxidans 
blood culture from November 2001 through January 2002. 
Controls were deﬁ  ned as patients who had no symptoms or 
signs of bloodstream infection (fever, chills, rigors, myalgias, 
nausea, vomiting, weakness, or hypotension). For each case-
patient, 5–7 controls were randomly selected and matched 
by the closest date of their visits to Ofﬁ  ce B to the case-
patient’s date of visit. Variables included age, sex, underly-
ing diagnosis, intravenous medications received, peripheral 
white blood cell counts, presence and type of central venous 
catheter (CVC), clinic visits, hospitalization dates, symp-
toms, and types of invasive procedures. Data were collected 
on standardized forms and analyzed by using Epi Info 2000 
version 1.1.2 (Centers for Disease Control and Prevention 
[CDC], Atlanta, GA, USA); odds ratios were used to esti-
mate risk, t tests were performed for continuous variables, 
and p<0.05 indicated statistical signiﬁ  cance.
Prospective Cohort Study
To identify possible A. xylosoxidans bloodstream in-
fection, ACDC conducted prospective blood culture sur-
veillance. On February 15, 2002, all patients with a CVC 
who had visited Ofﬁ  ce B since November 2001 were sent a 
letter requesting them to have a culture performed on blood 
drawn through the CVC. CVCs were removed from those 
whose culture results were positive.
Environmental Investigation
On January 17, 2002, numerous open containers (mul-
tidose 30-mL vials of heparin; 100-mL and 150-mL bottles 
of saline; and containers of alcohol, hydrogen peroxide, 
betadine, and iodine) were collected and sent to the Los 
Angeles County Public Health Laboratory for analysis. On 
February 15, 2002, environmental samples and swabs were 
collected for culture from work surfaces (e.g., countertops, 
sinks, hoods, kitchens) and from tap water and hands of 
healthcare workers who accessed CVCs, collected blood, 
prepared ﬂ  ushes, or administered chemotherapy.
Infection Control
During January and February 2002, we made several 
site visits to Ofﬁ  ce B to observe procedures, review medi-
cal records, and interview the ofﬁ  ce staff. Speciﬁ  cally, we 
observed procedures for preparation and administration of 
intravenous medications and asked ofﬁ  ce staff about level 
of technical training, experience, and license status.
Molecular Studies
Blood isolates of A. xylosoxidans from case-patients 
were obtained from Hospital A’s laboratory. For compari-
son, all A. xylosoxidans isolated from patients from Los 
Angeles County in the past 6 months were obtained from 
a large local reference laboratory. Pulsed-ﬁ  eld gel electro-
phoresis (PFGE) was performed at the Los Angeles County 
Public Health Laboratory by using standard methods (18) 
for Salmonella spp. with the exception that isolates were 
digested with XbaI and SpeI. PFGE pattern comparisons 
were performed visually by using criteria established by 
Tenover et al. (19).
Examination of CVC for Bioﬁ  lm
A CVC (PASport, a single-lumen, 6 French catheter 
with an under-the-skin titanium port; SIMS Deltec, Inc., St. 
Paul, MN, USA) was surgically removed from an asymp-
tomatic patient identiﬁ  ed in the prospective cohort study. 
Aseptic methods were used. The distal lumen opening was 
clamped with a sterile hemostat to retain the liquid within 
the lumen, and the catheter was placed in a sealed, sterile 
container and shipped overnight to CDC in Atlanta for pro-
cessing within 24 hours of collection. At CDC, the CVC 
was placed into a Class II Biological Safety Cabinet, and 
a 1-cm segment was removed with a sterile scalpel. This 
segment was cut lengthwise to expose the lumen, and the 
individual pieces were placed into 5% glutaraldehyde (Ted 
Pella, Redding, CA, USA) in 0.67 M cacodylate buffer, pH 
6.2, and processed for scanning electron microscopy (20). 
Samples were examined by using a Philips XL 20 Scan-
ning Electron Microscope (FEI Company, a subsidiary 
of Philips, Hillsboro, OR, USA). The remaining catheter 
attached to the titanium port was clamped, and the outer 
surface was cleaned with a 70% alcohol wipe, disinfected, 
and processed to recover bioﬁ  lm organisms (20). The re-
covered organisms were plated on trypticase soy agar con-
taining 5% sheep blood (blood agar; Becton, Dickinson, 
Sparks, MD, USA). Plates were incubated for up to 72 h at 
35°C and then examined. Colonies were spread onto blood 
agar for subculture and identiﬁ  ed by using standard clini-
cal microbiologic methods (21). Bioﬁ  lm isolates were also 
characterized by PFGE (methods described above).
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Results
A total of 12 patients with A. xylosoxidans blood-
stream infection were found: 9 from the retrospective 
case–control study and 3 from the prospective study 
(Table). All 12 were immunocompromised. Their ages 
ranged from 41 to 79 years (mean 65.8 years), and 10 
(83.3%) were female. Case-patients had differing un-
derlying diagnoses and chemotherapy regimens. Case-
patients had had fevers, chills, and/or rigors within min-
utes to days after an infusion through their CVC. Several 
case-patients had multiple episodes of fever and chills 
during and immediately after visits to Ofﬁ  ce B when their 
CVC was accessed for blood collection, chemotherapy, 
or routine ﬂ  ushes. For some, these symptoms were attrib-
uted to possible side effects of chemotherapy. All case-
patients had visited Ofﬁ  ce B from November 12 through 
December 18, 2001. Case-patient 1 was hospitalized from 
October 12 through November 10, 2001, and had visited 
Ofﬁ  ce B for daily collection to monitor neutropenia from 
November 13 through 19, 2001. Patients with A. xylosoxi-
dans bloodstream infection were treated with antimicro-
bial drugs and CVC removal. Available records showed 
case-patients were treated with piperacillin/tazobactam; 
1 case-patient who was allergic to penicillin was treated 
with aztreonam. One patient died from underlying malig-
nancy (end-stage pancreatic cancer).
Matched Case–Control Study
Of the 9 case-patients identiﬁ  ed, 7 who had clear onset 
date of bloodstream infection symptoms were selected for 
the case–control study. Case-patients were younger than 
controls (mean age 63.5 years [range 41–73 years] and 
mean age 73.2 years [range 35–89 years], respectively; p 
= 0.047). Case-patients were signiﬁ  cantly more likely to 
have a CVC than controls. Matched case–control analysis 
showed that all 7 case-patients versus 4 of 47 control pa-
tients had a CVC at the time of illness onset (p<0.0001). 
The 2 other case-patients not included in the case–control 
study also had CVCs. Patients with CVCs received hepa-
rin and saline ﬂ  ushes before and after the CVC was used 
for blood collection or infusions. No records documented 
when each of the Ofﬁ  ce B nurses accessed the CVCs. Pa-
tients without CVCs who needed only blood collection for 
testing did not receive any ﬂ  ushes; however, those without 
CVCs who needed blood tests before receiving an infusion 
received a heparin and saline ﬂ  ush after a peripheral in-
travenous line was placed. Case-patients and controls did 
not have statistically signiﬁ  cant differences in peripheral 
leukocyte counts, intravenous medications administered, 
types of chemotherapy received, or underlying diseases.
Prospective Cohort Study
In February 2002, 29 patients with CVCs had blood 
collected for culture. Of the 3 (10%) who had positive cul-
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Table. Characteristics of 12 case-patients with bacteremia caused by Alcaligenes xylosoxidans*
Case-patient
no. Age, y  Sex Underlying disease 
Date of CVC 
flush Date of onset, symptoms† 
Date of blood 
collection‡
Case–control study 
1 70 F Acute myelogenous 
leukemia
2001 Nov 19  2001 Nov 19, rigors after flush  2001 Nov 19 
2 65 F Breast cancer  2001 Dec 5  2001 Dec 5, no chart record of 
symptoms after flush, blood culture 
obtained next day 
2001 Dec 6 
3 73 F Colon cancer  2001 Dec 7  2001 Dec 7, fever after flush  2001 Dec 7 
4 41 F Sickle cell disease  2001 Dec 4  2001 Dec 11, myalgias, emesis  2001 Dec 11 
5 73 F Gastric cancer  Unknown  Unknown  2001 Dec 13 
6 71 M Colon cancer  2001 Dec18  2001 Dec 19, fever, chills  2001 Dec 20 
7 79 F Pancreatic cancer  Unknown  Unknown  2001 Dec 30 
8 45 F Breast cancer  2002 Jan 10  2002 Jan 10, no chart record of 
symptoms after flush, blood culture 
obtained next day 
2001 Jan 10 
9 70 F Non-Hodgkin 
lymphoma 
2002 Jan 10  2002 Jan 10, hypotension after 
infusion
2002 Jan 11 
Prospective study 
10 77 F Squamous cell cancer 
of palate 
NA 2001 Nov/Dec, intermittent nausea 
and weakness 
2002 Jan 29 
11 77 M Gastric cancer  NA 2001 Nov/Dec, intermittent fever, 
chills after flushes, not reported to 
Office B staff 
2002 Feb 7 
12 49 F Non-Hodgkin 
lymphoma 
NA Asymptomatic 2002 Feb 5
*CVC, central venous catheter; NA, not applicable. 
†Signs and symptoms of bloodstream infection. 
‡Collection of blood that had subsequent positive culture result for A. xylosoxidans.Alcaligenes xylosoxidans Bloodstream Infections 
ture results for A. xylosoxidans, chart review showed that 2 
had been intermittently symptomatic (Table).
Environmental Investigation
Cultures from available open solutions in the oncol-
ogy ofﬁ  ce, collected 6 weeks after the initial cluster of A. 
xylosoxidans–positive blood cultures, and environmental 
cultures did not grow A. xylosoxidans. A sample from a 
sterile saline bottle that was open in the infusion room was 
positive for Bacillus circulans, and a tap water sample was 
positive for Moraxella spp.
Infection Control Practices and Procedures
Ofﬁ  ce B had 10 patient examination rooms and a sepa-
rate, large, open infusion room where several patients could 
receive chemotherapy. The infusion room contained a hood 
and sink for preparation of intravenous medication. Of the 4 
staff members at Ofﬁ  ce B who regularly accessed CVCs; in-
serted peripheral intravenous catheters; collected blood; and 
prepared or administered chemotherapy, ﬂ  ushes, or intrave-
nous medications, only 1 was a registered nurse who had 
a California state license. The 3 nonlicensed staff members 
were reported to have received nursing training in their na-
tive country but did not have documented formal training 
or education. One nurse wore artiﬁ  cial ﬁ  ngernails but had 
removed them before hand culture samples were collected; 
thus, the ﬁ  ngernails were unavailable for culture. The fol-
lowing breaches in infection control were noted: intrave-
nous catheters were inserted by persons not wearing gloves; 
unlabeled, preﬁ  lled syringes were stored in the hood; no 
documentation of hood cleaning was found; open, multidose 
heparin vials and saline bottles, some undated, were found 
throughout the facility; nonhygienic material was stored in 
the chemotherapy medication preparation hood; and failure 
to wash hands between patients was noted. No pharmacists 
were employed at Ofﬁ  ce B. No documentation of staff train-
ing and evaluation for chemotherapy preparation or infection 
control competency was available.
CVC Bioﬁ  lm Studies
Scanning electron microscopy of the CVC showed a 
bioﬁ  lm that contained rod-shaped bacteria in association 
with ﬁ  brinlike material on the catheter surface (Figure 1). 
A pure bacterial culture recovered from the CVC lumen 
was identiﬁ  ed as A. xylosoxidans.
Molecular Studies
A. xylosoxidans blood culture isolates from case-pa-
tients were indistinguishable by PFGE analysis (Figure 2); 
in contrast, 3 A. xylosoxidans isolates from a local refer-
ence laboratory had different PFGE patterns. The isolate 
from the CVC bioﬁ  lm matched the A. xylosoxidans blood-
stream infection outbreak strain.
Discussion
This large outbreak (N = 12) of A. xylosoxidans blood-
stream infections was caused by 1 strain, which was also iso-
lated from CVC bioﬁ  lm. Symptoms of bloodstream infection 
probably occurred when ﬂ  ushes detached bacteria from the 
CVC bioﬁ  lm. The prospective study found that 3 (10%) of 
29 patients had A. xylosoxidans–positive blood cultures. Our 
case–control and prospective studies support the association 
of A. xylosoxidans bloodstream infection and CVCs, and our 
molecular biologic studies conﬁ  rm A. xylosoxidans bioﬁ  lm 
of the same outbreak strain on a CVC. A. xylosoxidans out-
breaks reported to date have been associated with healthcare 
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Figure 1. Scanning electron micrograph of lumen of segment of 
central venous catheter removed from an asymptomatic patient. 
Bioﬁ  lm contains rod-shaped bacteria (Alcaligenes xylosoxidans) in 
association with ﬁ  brinlike material on the catheter surface. 
Figure 2. Pulsed-ﬁ  eld gel electrophoresis of isolates from patients 
with  Alcaligenes xylosoxidans bloodstream infection. Lane 1, 
laboratory standard; lanes 2 and 6, community strains of A. 
xylosoxidans; lanes 3–5 and 7–13, outbreak strains; lane 14, 
central venous catheter (CVC) port bioﬁ  lm outbreak strain; lane 15, 
CVC port outbreak stain.RESEARCH
and contamination of hospital products (1,2,5,12–14), but 
none occurred in an outpatient setting.
The cause of this outbreak most likely was the use of 
contaminated multidose vials of heparin or saline ﬂ  ushes, 
leading to the formation of an A. xylosoxidans bioﬁ  lm on 
CVCs. Case-patient 1 had been hospitalized from late Octo-
ber through early November at Hospital A. During Novem-
ber 13–19, 2001, this case-patient had had blood collected 
and her CVC line ﬂ  ushed numerous times at Ofﬁ  ce B; on 
November 19, culture result indicated A. xylosoxidans infec-
tion, which was successfully treated. We observed multiple 
breaches in infection control at Ofﬁ  ce B: use of unlabeled, 
preﬁ  lled syringes, poor hand hygiene, and lack of glove 
use. The CVC of case-patient 1 may have been ﬂ  ushed by 
using the same syringe and needle inserted into multidose 
vials, causing contamination of the vials.  Another possible 
route of contamination is through artiﬁ  cial ﬁ  ngernails. A 
cluster of Serratia marcescens and A. xylosoxidans bacter-
emia cases linked to multidose heparin vials contaminated 
by a nurse with artiﬁ  cial ﬁ  ngernails has been reported (22); 
however, the artiﬁ  cial ﬁ  ngernails from the nurse at Ofﬁ  ce 
B were unavailable for testing. We suspect that multidose 
vials were contaminated with A. xylosoxidans and subse-
quently used on other patients from November 12 through 
December 18, 2001, when all case-patients had overlapping 
visits at Ofﬁ  ce B and received CVC ﬂ  ushes. A culture from 
an open, supposedly sterile saline bottle grew B. circulans, 
which suggests possible breaches in infection control. Mul-
tidose heparin and saline vials have been reported as the 
cause of outbreaks of hepatitis C (23,24), S. marcescens 
(25), and Pseudomonas aeruginosa (26) infections.
Although the heparin and the saline vials could have 
been contaminated from case-patient 1 in November, case-
patients who subsequently received ﬂ  ushes from these vials 
may not have become immediately ill with symptoms of 
bloodstream infection. A. xylosoxidans bioﬁ  lm could have 
developed on their CVCs and intermittently caused clini-
cal illness when the CVCs were manipulated; i.e., ﬂ  ushing 
dislodged the bioﬁ  lm and caused symptomatic bacteremia. 
Although indwelling catheters are frequently colonized 
with bioﬁ  lm shortly after insertion (27), colonization does 
not necessarily lead to infection; bloodstream infection 
symptoms from an organism in contaminated intravenous 
solutions have been delayed for as long as 421 days af-
ter exposure (28). The ﬁ  nding of an asymptomatic patient 
with a CVC with A. xylosoxidans bioﬁ  lm supports this. A 
number of variables may be associated with detachment of 
microbial cells from a bioﬁ  lm (29), resulting in erosion or 
sloughing. Flushing, which could mechanically shear the 
bioﬁ  lm, could result in detachment of cells or aggregates 
that could in turn colonize the bloodstream and cause signs 
and symptoms of bacteremia. This phenomenon has been 
recently reported (28).
The case-patients in this outbreak had their CVCs 
removed and were treated with antimicrobial agents. The 
presence of A. xylosoxidans bioﬁ  lm and the mechanism of 
bloodstream infection after disruption by catheter ﬂ  ushing 
suggests that eradication of infection would require cath-
eter removal, as reported by others (4,9). Previously, recur-
rent A. xylosoxidans bacteremia has been reported in those 
patients whose indwelling catheters were not removed (11). 
Formation of A. xylosoxidans bioﬁ  lm provides an explana-
tion for the organism most commonly causing bacteremia 
in patients with CVCs (7,10).
The California Code of Regulations, Title 17, Section 
2500 (30), requires all healthcare professionals to immedi-
ately report outbreaks of any cause; however, this outbreak 
was not recognized early on. The initial cluster of patients at 
Ofﬁ  ce B had symptoms and positive blood cultures growing 
this uncommon organism for 6 weeks before the cases were 
reported to the Los Angeles County Department of Public 
Health. Because outpatient settings may lack surveillance 
systems, outbreaks may not be recognized immediately, 
thus potentially exposing more patients. In addition, some 
of the symptoms of bloodstream infection were initially at-
tributed to side effects of chemotherapy. Because 10% of 
patients in our prospective cohort study had blood cultures 
positive for A. xylosoxidans, further studies are needed to 
determine whether active surveillance for patients with 
CVCs would help recognize infections.
Because we noted not only infection control breaches 
but also that unlicensed ofﬁ  ce personnel were manipulat-
ing the CVCs, line ﬂ  ushes, infusions, and blood collection 
through CVCs, we reported the situation to the California 
Medical Board and the California Department of Health 
Services. Although no California state regulations for in-
fection control in outpatient physician’s ofﬁ  ces exist, the 
California Department of Health Services and Los Angeles 
County Department of Public Health recommended that the 
oncology ofﬁ  ce improve infection control standards; han-
dling, storage, exposure, and access to pharmaceuticals; 
and improve medical record documentation. New infec-
tion control policies were established, and the ofﬁ  ce sub-
sequently hired new, properly licensed registered nurses 
and nurse practitioners to handle insertion of intravenous 
catheters and administration of intravenous medications 
and chemotherapy. After proper education of the oncol-
ogy ofﬁ  ce staff and removal of multidose vials of heparin 
and saline, no more A. xylosoxidans bloodstream infections 
were reported from Ofﬁ  ce B.
Our investigation has limitations. We did not culture 
A. xylosoxidans from the multidose vials. The original vi-
als, used when the outbreak began, had already been dis-
carded and were not available for testing by the time we 
were notiﬁ  ed in January 2002. Our investigation was also 
limited by the absence of medical records indicating when 
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nursing staff accessed the CVCs. Although the contami-
nation of multidose vials remains suggestive, we suspect 
that they were the most likely source. The outbreak ended 
after discontinuing their use and enacting improved infec-
tion control practices. The organism could have been in-
troduced into multidose vials by a needle or syringe used 
on an infected patient or by the artiﬁ  cial ﬁ  ngernails of the 
nurse, through gaps in infection control.
For patients who received infusion therapy at home, re-
ceipt of therapy in an outpatient clinic or physician’s ofﬁ  ce 
was an independent risk factor for bloodstream infection 
(31). Therefore, clinicians need to be vigilant because mi-
nor breaches in infection control can lead to large outbreaks 
with uncommon human pathogens, especially in patients 
with CVCs. Clinicians also need to ensure that appropri-
ate infection control practices are adhered to consistently, 
especially in outpatient care settings, where oversight of in-
fection control procedures may be absent. Unlike standards 
that exist for nursing homes or hospitals, no written stan-
dards regarding infection control in outpatient settings exist 
from the California Department of Health Services or the 
California Medical Board. However, routine monitoring 
and adherence to infection control could prevent outbreaks. 
Clinicians providing care in outpatient settings should re-
view appropriate infection control standards and consider 
establishing written policies to ensure that standards are 
met. As healthcare delivery continues to move toward out-
patient care (32), the lack of formal infection control pro-
cedures and accountability in the outpatient ofﬁ  ce setting 
can lead to large disease outbreaks (33,34); the need for 
oversight in this setting should be considered.
Our investigation helps characterize the mechanisms 
of A. xylosoxidans bloodstream infection in immunocom-
promised patients with CVCs. It provides a better under-
standing of how bioﬁ  lm formation in a CVC can result in 
a clinical infectious disease process with this uncommon 
organism. Substantial illness and death can occur in out-
patient settings that lack formal oversight. This outbreak 
highlights an unaddressed infection control problem in 
the outpatient setting for regulating agencies to further 
review.
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